Current Opinion in Biotechnology, Journal Year: 2024, Volume and Issue: 91, P. 103248 - 103248
Published: Dec. 31, 2024
Language: Английский
Nature Communications, Journal Year: 2025, Volume and Issue: 16(1)
Published: Jan. 17, 2025
The effect of fermented foods on healthy human gut microbiota structure and function, particularly its seasonal preference frequent long-term consumption, has been largely uncharacterised. Here, we assess the metabolite composition 78 Indian agrarian individuals who differ in intake milk soybean products by sampling during hot-humid summer, autumn dry winter. Here show that, shifts between Prevotella- Bifidobacterium/Ruminococcus-driven community types, or ecological states, associated fatty acid derivatives, with a bimodal change Bacteroidota consumers. Our results associate food consumption reduced diversity bacterial load. We identify taxonomic groups that drive fluctuation two states microbiota. This understanding may pave way towards developing strategies to sustain resilient through dietary interventions.
Language: Английский
Citations
1
Trends in Microbiology, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 1, 2025
Language: Английский
Citations
1
Ageing Research Reviews, Journal Year: 2024, Volume and Issue: 103, P. 102585 - 102585
Published: Nov. 23, 2024
The complex gut microbiome influences host aging and plays an important role in the manifestation of age-related diseases. Restoring a healthy via Fecal Microbiota Transplantation (FMT) is receiving extensive consideration to therapeutically transfer longevity. Herein, we comprehensively review benefits microbial rejuvenation - FMT promote aging, with few studies documenting life length properties. This explores how preconditioning donors standard lifestyle pharmacological antiaging interventions reshape microbiome, resulting being also FMT-transferable. Finally, expose current clinical uses context therapy address challenges regulatory landscape, protocol standardization, health risks that require refinement effectively utilize elderly.
Language: Английский
Citations
4
Microbiome, Journal Year: 2024, Volume and Issue: 12(1)
Published: Dec. 18, 2024
In recent years, human microbiome research has flourished and drawn attention from both healthcare professionals general consumers as the is now recognized having a significant influence on health. This led to emergence of companies offering testing services. Some these services are sold directly consumer via companies' websites or medical laboratory websites. order provide an overview experience proposed by services, one single faecal sample was sent six different (five based in Europe USA). Two out kits were commercialized laboratories, but without any requirement for prescription. The analyses reports received discussed with panel experts (21 8 countries) during online workshop. workshop identification several limitations challenges related kits, including over-promising messages companies, lack transparency methodology used analysis reliability results. considered interpretations recommendations provided be premature due robust scientific evidence associated limited clinical utility. also grey areas surrounding regulatory status test their positioning European market. recommended distinction between requirements intended use purpose kit: hand, developed satisfy curiosity, clear mention this objective, no disease risk disease, other vitro diagnostic (IVD) CE-marked which could go deeper into interpretation samples, such report would trained professionals. Recommendations actions, specific context listed improve quality robustness meet expectations end users (consumers, patients professionals). need standardization, evidence, qualification microbiome-based biomarkers main issues that will require near future align development societal needs thus foster translation daily health practice.
Language: Английский
Citations
4
Nature Microbiology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 22, 2025
Language: Английский
Citations
0
Deleted Journal, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 27, 2025
Die intestinale Mikrobiota umfasst alle lebenden Mikroorganismen im Gastrointestinaltrakt und ist entscheidend für die Funktion des Magen-Darm-Trakts. Klinische Beobachtungen sowie Laborexperimente belegen eine zentrale Rolle der bei chronisch-entzündlichen Darmerkrankungen (CED). Viele mechanistische Details sind jedoch unklar. Es werden Veränderungen deren kausaler Zusammenhang mit Pathogenese von CED beschrieben. Aktuelle zukünftige diagnostische therapeutische Möglichkeiten diskutiert. Narratives Review. Patienten in ihrer Zusammensetzung, Diversität verändert, spezifische (universale) CED-definierende Bakterien konnten bis jetzt nicht gefunden werden. gesunde hat zahlreiche entzündungshemmende Funktionen, darunter Produktion kurzkettiger Fettsäuren oder Kompetition Pathogenen. CED-Mikrobiota wirkt dagegen durch Destruktion intestinalen Barriere direkte Interaktion dem Immunsystem entzündungsfördernd. Balance zwischen pro- antiinflammatorischen Wirkungen scheint Entstehung Darmentzündung zu sein. Eine mikrobiotabasierte CED-Diagnostik vielversprechend, aber noch den klinischen Einsatz bereit. Probiotika fäkale Mikrobiotatransplantation haben klinische Effekte vor allem Colitis ulcerosa, das Potenzial mikrobiotabasierter Therapien wird annährend ausgeschöpft. CED-Dysbiose bleibt undefiniert. unklar, wie vielen parallel existierenden antientzündlichen Mechanismen zur CED-Pathogenese beitragen. Das unzureichende Verständnis erschwert Entwicklung Diagnostik Therapien.
Citations
0
The Journal of Physiology, Journal Year: 2025, Volume and Issue: unknown
Published: March 1, 2025
Language: Английский
Citations
0
Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12
Published: March 17, 2025
The human gut microbiota, an intricate ecosystem of bacteria, viruses, fungi, and archaea, plays a pivotal role in maintaining gastrointestinal (GI) homeostasis (1). Recent advancements microbiome research have unveiled its profound influence on various GI disorders, including gastric cancer, inflammatory bowel disease (IBD), irritable syndrome (IBS), acute pancreatitis, Clostridioides difficile infection (CDI) (2). Understanding the interplay between microbiota these disorders offers promising avenues for novel therapeutic interventions, next-generation probiotics, fecal transplantation (FMT), targeted microbiome-oriented modulation (3,4).Gastric cancer remains significant global health burden, ranking as fourth leading cause cancer-related mortality. Dysbiosis, characterized by altered microbial diversity composition, is hallmark carcinogenesis (Marashi et al.). Helicobacter pylori wellestablished risk factor, yet eradication alone does not fully restore equilibrium. Studies suggest that certain bacterial species, such Lactobacillus, enhance immunotherapy responses, whereas antibiotic-induced dysbiosis can reduce efficacy chemotherapy al.) (5,6). Probiotic supplementation post-gastrectomy has demonstrated potential mitigating inflammation fostering healthier milieu (7). IBD, encompassing Crohn's ulcerative colitis, immune-mediated disorder driven complex genetic, environmental, factors (Ning (8). Dysbiosis relationship metabolic functions extends beyond tract. Emerging explored bidirectional connection insulin-like growth factor 1 (IGF-1), key regulator growth-related pathways (Zheng been implicated modulating IGF-1 levels, suggesting consequences imbalances. This insight broadens scope microbiome-targeted therapies to include alongside diseases.The expanding knowledge underscores need precision medicine approaches. Personalized profiling could guide tailored optimizing outcomes. Probiotics, prebiotics, synbiotics, nextgeneration microbiome-based therapies, engineered consortia postbiotics, offer exciting prospects. Moreover, metagenomics metabolomics will further elucidate host-microbe interactions, paving way strategies (13).In conclusion, published studies this Research Topic highlight integral determinant disease. From IBS multifaceted (Stange Harnessing interventions holds immense revolutionizing management, shifting from symptomatic treatment root-cause (14). As continues unravel complexities future gastroenterology lies leveraging microscopic powerhouse transformative healthcare solutions.
Language: Английский
Citations
0
Metabolites, Journal Year: 2025, Volume and Issue: 15(4), P. 213 - 213
Published: March 21, 2025
Background/Objectives: Currently, the diagnosis of autism spectrum disorder (ASD) relies on behavioral observations, frequently causing delays in early identification. Prognostic markers are essential for customizing therapy and monitoring progress. However, there currently no recognized biomarkers ASD. The current systematic review aims to analyze studies intestinal metabolome children (both autistic non-autistic) identify potential metabolites diagnostic prognostic purposes. Methods: We searched Medline, Scopus, Embase, Web Science relevant publications. Results: identified 11 examining gut that distinguished between non-autistic children. These also revealed connections metabolites, developmental scores, symptoms. substances were associated with metabolic pathways such as amino acids, vitamins, lipids, oxidative stress, glycans, xenobiotics, nucleotides. Conclusions: findings suggest changes may be linked causes or development autism. Although these observations came from a few reports, only high-quality included this review. Further research is confirm biomarkers.
Language: Английский
Citations
0
npj Biofilms and Microbiomes, Journal Year: 2025, Volume and Issue: 11(1)
Published: March 28, 2025
The emergence of a broad spectrum microbiome-based therapies has triggered changes in European regulatory frameworks. first part the review describes these innovative therapies. second provides an overview current framework and key introduced by Regulation on substances human origin (SoHO) for development therapies, highlighting need microbiome science to unlock full potential
Language: Английский
Citations
0